SRC and liver cancer: We examined different tyrosine kinase inhibitors (TKIs) except FDA-approved drugs for liver cancer, including EGFR inhibitors (erlorinib, neratinib, dacomitinib, and gefitinib), FGFR or VEGFR inhibitors (dovitinib, vandetanib, danusertib, sunitinib, and vatalanib), Src inhibitors (bosutinib, saracatinib, and dasatinib), and other multiple TKIs (masitinib and crizotinib).